Autoantibody predictors of gastrointestinal symptoms in systemic sclerosis

Abstract Objectives To assess the prevalence and burden of SSc-related gastrointestinal dysfunction (SSc-GI) and to evaluate associations with demographic, clinical and serological characteristics. Methods Patients completed the UCLA SCTC GIT 2.0 questionnaire for SSc-GI disease to assess the burden...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Rheumatology (Oxford, England) England), 2022-02, Vol.61 (2), p.781-786
Hauptverfasser: Ahmed, Fiza, Maclean, Rory H, Nihtyanova, Svetlana I, Ong, Voon H, Murray, Charles D, Denton, Christopher P
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 786
container_issue 2
container_start_page 781
container_title Rheumatology (Oxford, England)
container_volume 61
creator Ahmed, Fiza
Maclean, Rory H
Nihtyanova, Svetlana I
Ong, Voon H
Murray, Charles D
Denton, Christopher P
description Abstract Objectives To assess the prevalence and burden of SSc-related gastrointestinal dysfunction (SSc-GI) and to evaluate associations with demographic, clinical and serological characteristics. Methods Patients completed the UCLA SCTC GIT 2.0 questionnaire for SSc-GI disease to assess the burden of GI disease across multiple functional and psychological domains. Questionnaire scores were assessed using non-parametric and quantile regression analyses. Results Our cohort included 526 patients with SSc, with a typical distribution of disease-associated autoantibodies (ACA, ARA, ATA, PM-Scl, U1RNP, U3RNP). We demonstrated associations between hallmark antibodies and the domain-specific burden of GI disease. In particular, ACA, ARA and ENA-negative demonstrated increased SSc-GI disease burden, while PM-Scl conferred relative protection. In a distributional analysis, associations with autoantibodies were particularly marked in those with the highest burden of GI disease. Conclusion There is a significant burden of SSc-GI disease in patients with SSc; reflux and bloating symptoms are most prominent. SSc hallmark antibodies may predict increased risk of SSc-GI disease, in particular ACA and ARA, while PM-Scl may be protective.
doi_str_mv 10.1093/rheumatology/keab395
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2519805951</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/rheumatology/keab395</oup_id><sourcerecordid>2519805951</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-fe8306c603c2c0f2104b299ad8d17762f600130aba404926e20d52d8965ccc413</originalsourceid><addsrcrecordid>eNqNkD9PwzAUxC0EoqXwDRDKyBL6bMdpPFYVf1WJBebIcZxiSOLg5wz59qRKqRiZ3g2_u3c6Qq4p3FGQfOk_TN-o4Gq3G5ZfRhVcihMyp0nKYuCcnR41S2bkAvETAATl2TmZcS5BZlLMycu6D061wRauHKLOm9Lq4DxGrop2CoN3tg0Gg21VHeHQdME1GNl21BhMY3WEujbeocVLclapGs3V4S7I-8P92-Yp3r4-Pm_W21hzyUNcmYxDqlPgmmmoGIWkYFKqMivpapWyKgWgHFShEkgkSw2DUrAyk6nQWieUL8jtlNt5992P3fLGojZ1rVrjesyZoDIDIcUeTSZUjw3RmyrvvG2UH3IK-X7F_O-K-WHF0XZz-NAXjSmPpt_ZRmA5Aa7v_hf5Ax-whPc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2519805951</pqid></control><display><type>article</type><title>Autoantibody predictors of gastrointestinal symptoms in systemic sclerosis</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Ahmed, Fiza ; Maclean, Rory H ; Nihtyanova, Svetlana I ; Ong, Voon H ; Murray, Charles D ; Denton, Christopher P</creator><creatorcontrib>Ahmed, Fiza ; Maclean, Rory H ; Nihtyanova, Svetlana I ; Ong, Voon H ; Murray, Charles D ; Denton, Christopher P</creatorcontrib><description>Abstract Objectives To assess the prevalence and burden of SSc-related gastrointestinal dysfunction (SSc-GI) and to evaluate associations with demographic, clinical and serological characteristics. Methods Patients completed the UCLA SCTC GIT 2.0 questionnaire for SSc-GI disease to assess the burden of GI disease across multiple functional and psychological domains. Questionnaire scores were assessed using non-parametric and quantile regression analyses. Results Our cohort included 526 patients with SSc, with a typical distribution of disease-associated autoantibodies (ACA, ARA, ATA, PM-Scl, U1RNP, U3RNP). We demonstrated associations between hallmark antibodies and the domain-specific burden of GI disease. In particular, ACA, ARA and ENA-negative demonstrated increased SSc-GI disease burden, while PM-Scl conferred relative protection. In a distributional analysis, associations with autoantibodies were particularly marked in those with the highest burden of GI disease. Conclusion There is a significant burden of SSc-GI disease in patients with SSc; reflux and bloating symptoms are most prominent. SSc hallmark antibodies may predict increased risk of SSc-GI disease, in particular ACA and ARA, while PM-Scl may be protective.</description><identifier>ISSN: 1462-0324</identifier><identifier>EISSN: 1462-0332</identifier><identifier>DOI: 10.1093/rheumatology/keab395</identifier><identifier>PMID: 33909895</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Antibodies, Antinuclear - immunology ; Autoantibodies - immunology ; Female ; Gastrointestinal Diseases - etiology ; Gastrointestinal Diseases - immunology ; Humans ; Male ; Middle Aged ; Regression Analysis ; Scleroderma, Systemic - complications ; Scleroderma, Systemic - immunology ; Scleroderma, Systemic - pathology ; Statistics, Nonparametric ; Surveys and Questionnaires</subject><ispartof>Rheumatology (Oxford, England), 2022-02, Vol.61 (2), p.781-786</ispartof><rights>The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com 2021</rights><rights>The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-fe8306c603c2c0f2104b299ad8d17762f600130aba404926e20d52d8965ccc413</citedby><cites>FETCH-LOGICAL-c393t-fe8306c603c2c0f2104b299ad8d17762f600130aba404926e20d52d8965ccc413</cites><orcidid>0000-0003-3975-8938 ; 0000-0002-9686-0501 ; 0000-0001-5474-0053</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1578,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33909895$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ahmed, Fiza</creatorcontrib><creatorcontrib>Maclean, Rory H</creatorcontrib><creatorcontrib>Nihtyanova, Svetlana I</creatorcontrib><creatorcontrib>Ong, Voon H</creatorcontrib><creatorcontrib>Murray, Charles D</creatorcontrib><creatorcontrib>Denton, Christopher P</creatorcontrib><title>Autoantibody predictors of gastrointestinal symptoms in systemic sclerosis</title><title>Rheumatology (Oxford, England)</title><addtitle>Rheumatology (Oxford)</addtitle><description>Abstract Objectives To assess the prevalence and burden of SSc-related gastrointestinal dysfunction (SSc-GI) and to evaluate associations with demographic, clinical and serological characteristics. Methods Patients completed the UCLA SCTC GIT 2.0 questionnaire for SSc-GI disease to assess the burden of GI disease across multiple functional and psychological domains. Questionnaire scores were assessed using non-parametric and quantile regression analyses. Results Our cohort included 526 patients with SSc, with a typical distribution of disease-associated autoantibodies (ACA, ARA, ATA, PM-Scl, U1RNP, U3RNP). We demonstrated associations between hallmark antibodies and the domain-specific burden of GI disease. In particular, ACA, ARA and ENA-negative demonstrated increased SSc-GI disease burden, while PM-Scl conferred relative protection. In a distributional analysis, associations with autoantibodies were particularly marked in those with the highest burden of GI disease. Conclusion There is a significant burden of SSc-GI disease in patients with SSc; reflux and bloating symptoms are most prominent. SSc hallmark antibodies may predict increased risk of SSc-GI disease, in particular ACA and ARA, while PM-Scl may be protective.</description><subject>Antibodies, Antinuclear - immunology</subject><subject>Autoantibodies - immunology</subject><subject>Female</subject><subject>Gastrointestinal Diseases - etiology</subject><subject>Gastrointestinal Diseases - immunology</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Regression Analysis</subject><subject>Scleroderma, Systemic - complications</subject><subject>Scleroderma, Systemic - immunology</subject><subject>Scleroderma, Systemic - pathology</subject><subject>Statistics, Nonparametric</subject><subject>Surveys and Questionnaires</subject><issn>1462-0324</issn><issn>1462-0332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkD9PwzAUxC0EoqXwDRDKyBL6bMdpPFYVf1WJBebIcZxiSOLg5wz59qRKqRiZ3g2_u3c6Qq4p3FGQfOk_TN-o4Gq3G5ZfRhVcihMyp0nKYuCcnR41S2bkAvETAATl2TmZcS5BZlLMycu6D061wRauHKLOm9Lq4DxGrop2CoN3tg0Gg21VHeHQdME1GNl21BhMY3WEujbeocVLclapGs3V4S7I-8P92-Yp3r4-Pm_W21hzyUNcmYxDqlPgmmmoGIWkYFKqMivpapWyKgWgHFShEkgkSw2DUrAyk6nQWieUL8jtlNt5992P3fLGojZ1rVrjesyZoDIDIcUeTSZUjw3RmyrvvG2UH3IK-X7F_O-K-WHF0XZz-NAXjSmPpt_ZRmA5Aa7v_hf5Ax-whPc</recordid><startdate>20220202</startdate><enddate>20220202</enddate><creator>Ahmed, Fiza</creator><creator>Maclean, Rory H</creator><creator>Nihtyanova, Svetlana I</creator><creator>Ong, Voon H</creator><creator>Murray, Charles D</creator><creator>Denton, Christopher P</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3975-8938</orcidid><orcidid>https://orcid.org/0000-0002-9686-0501</orcidid><orcidid>https://orcid.org/0000-0001-5474-0053</orcidid></search><sort><creationdate>20220202</creationdate><title>Autoantibody predictors of gastrointestinal symptoms in systemic sclerosis</title><author>Ahmed, Fiza ; Maclean, Rory H ; Nihtyanova, Svetlana I ; Ong, Voon H ; Murray, Charles D ; Denton, Christopher P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-fe8306c603c2c0f2104b299ad8d17762f600130aba404926e20d52d8965ccc413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antibodies, Antinuclear - immunology</topic><topic>Autoantibodies - immunology</topic><topic>Female</topic><topic>Gastrointestinal Diseases - etiology</topic><topic>Gastrointestinal Diseases - immunology</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Regression Analysis</topic><topic>Scleroderma, Systemic - complications</topic><topic>Scleroderma, Systemic - immunology</topic><topic>Scleroderma, Systemic - pathology</topic><topic>Statistics, Nonparametric</topic><topic>Surveys and Questionnaires</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ahmed, Fiza</creatorcontrib><creatorcontrib>Maclean, Rory H</creatorcontrib><creatorcontrib>Nihtyanova, Svetlana I</creatorcontrib><creatorcontrib>Ong, Voon H</creatorcontrib><creatorcontrib>Murray, Charles D</creatorcontrib><creatorcontrib>Denton, Christopher P</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Rheumatology (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ahmed, Fiza</au><au>Maclean, Rory H</au><au>Nihtyanova, Svetlana I</au><au>Ong, Voon H</au><au>Murray, Charles D</au><au>Denton, Christopher P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Autoantibody predictors of gastrointestinal symptoms in systemic sclerosis</atitle><jtitle>Rheumatology (Oxford, England)</jtitle><addtitle>Rheumatology (Oxford)</addtitle><date>2022-02-02</date><risdate>2022</risdate><volume>61</volume><issue>2</issue><spage>781</spage><epage>786</epage><pages>781-786</pages><issn>1462-0324</issn><eissn>1462-0332</eissn><abstract>Abstract Objectives To assess the prevalence and burden of SSc-related gastrointestinal dysfunction (SSc-GI) and to evaluate associations with demographic, clinical and serological characteristics. Methods Patients completed the UCLA SCTC GIT 2.0 questionnaire for SSc-GI disease to assess the burden of GI disease across multiple functional and psychological domains. Questionnaire scores were assessed using non-parametric and quantile regression analyses. Results Our cohort included 526 patients with SSc, with a typical distribution of disease-associated autoantibodies (ACA, ARA, ATA, PM-Scl, U1RNP, U3RNP). We demonstrated associations between hallmark antibodies and the domain-specific burden of GI disease. In particular, ACA, ARA and ENA-negative demonstrated increased SSc-GI disease burden, while PM-Scl conferred relative protection. In a distributional analysis, associations with autoantibodies were particularly marked in those with the highest burden of GI disease. Conclusion There is a significant burden of SSc-GI disease in patients with SSc; reflux and bloating symptoms are most prominent. SSc hallmark antibodies may predict increased risk of SSc-GI disease, in particular ACA and ARA, while PM-Scl may be protective.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>33909895</pmid><doi>10.1093/rheumatology/keab395</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-3975-8938</orcidid><orcidid>https://orcid.org/0000-0002-9686-0501</orcidid><orcidid>https://orcid.org/0000-0001-5474-0053</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1462-0324
ispartof Rheumatology (Oxford, England), 2022-02, Vol.61 (2), p.781-786
issn 1462-0324
1462-0332
language eng
recordid cdi_proquest_miscellaneous_2519805951
source Oxford University Press Journals All Titles (1996-Current); MEDLINE; Alma/SFX Local Collection
subjects Antibodies, Antinuclear - immunology
Autoantibodies - immunology
Female
Gastrointestinal Diseases - etiology
Gastrointestinal Diseases - immunology
Humans
Male
Middle Aged
Regression Analysis
Scleroderma, Systemic - complications
Scleroderma, Systemic - immunology
Scleroderma, Systemic - pathology
Statistics, Nonparametric
Surveys and Questionnaires
title Autoantibody predictors of gastrointestinal symptoms in systemic sclerosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T16%3A28%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Autoantibody%20predictors%20of%20gastrointestinal%20symptoms%20in%20systemic%20sclerosis&rft.jtitle=Rheumatology%20(Oxford,%20England)&rft.au=Ahmed,%20Fiza&rft.date=2022-02-02&rft.volume=61&rft.issue=2&rft.spage=781&rft.epage=786&rft.pages=781-786&rft.issn=1462-0324&rft.eissn=1462-0332&rft_id=info:doi/10.1093/rheumatology/keab395&rft_dat=%3Cproquest_cross%3E2519805951%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2519805951&rft_id=info:pmid/33909895&rft_oup_id=10.1093/rheumatology/keab395&rfr_iscdi=true